Pentixapharm Holding AG (PTP.F)
Key Executives
| Name | Title | Pay | Exercised | Year Born |
|---|---|---|---|---|
| Mr. Dirk Pleimes M.D. | Group CEO, Chief Medical Officer & Member of Management Board | -- | -- | 1975 |
| Ms. Jenny Schewe | Head of Finance & Controlling | -- | -- | -- |
| Mr. Henner Kollenberg | Member of Management Board & Chief Business Officer | -- | -- | 1968 |
| Dr. Patrik Kehler | Chief Scientific Officer | -- | -- | 1986 |
| Dr. Simone Pickel | Head of Clinical Therapy | -- | -- | -- |
| Dr. Antje Danielczyk | Head of R&D Operations | -- | -- | -- |
| Dr. Neydher Berroteran-Infante | Head of CMC | -- | -- | -- |
| Dr. Alessandra Bierwagen | Head of Regulatory | -- | -- | -- |
| Dr. Anna Janz | Head of Clinical Diagnostics | -- | -- | -- |
Pentixapharm Holding AG
- Sector:
- Healthcare
- Industry: Biotechnology
- Full Time Employees:
- 75
Description
Pentixapharm Holding AG operates as a clinical-stage radiopharmaceutical development company. It focuses on developing CXCR4 ligand-based radiopharmaceutical approaches for diagnostic and therapeutic programs in various hematological and solid cancers, as well as cardiovascular, endocrine, and inflammatory diseases. The company's clinical pipeline includes PentixaTher, an Yttrium-90-based therapeutic against non-Hodgkin lymphomas; and PentixaFor, a Gallium-68-based companion diagnostic. Its clinical studies for compounds have commenced in Europe, including a dose-finding study for PentixaTher and a Phase III registration study for PentixaFor in marginal zone lymphoma. In addition, the company's PentixaFor is being developed as a diagnostic tool for primary aldosteronism, a cause of hypertension. Pentixapharm Holding AG was founded in 2019 and is based in Berlin, Germany.
Corporate Governance
Upcoming Events
Upcoming Events Information Not Available
Recent Events
Recent Events Information Not Available